ExpansionOpportunity Cerapedics is expanding its Colorado headquarters and manufacturing/ R&D footprint to support growth of FDA approved i-FACTOR and the next-generation bone graft, presenting an opportunity to upsell process automation, facility-scale supply partnerships, and optimized logistics with local distributors or contract manufacturers.

SalesGrowth With revenue in the upper hundreds of millions and rapid hiring in Colorado (over 100 hires in five years, plus plans for 60 more by end of 2024), there is potential to target regional clinical teams, distributors, and hospital networks for expanded adoption of i-FACTOR and PearlMatrix grafts, including spine and orthopedic trauma applications.

FDA-Approved traction Two FDA-approved products powered by P-15 peptide indicate strong safety and efficacy signals, suggesting partnership opportunities with surgeons and hospital systems for broader A-to-Z bone repair solutions, bundled with training and support programs to drive higher adoption in spine procedures.

ClinicalEvidence Long-term IDE study follow-up data for i-FACTOR peptide-enhanced bone graft improves credibility; sales plays can emphasize evidence-based outcomes to win procurement discussions, expand KOL engagement, and accelerate hospital trial adoption in spine centers.

StrategicPartners Growing presence in a global orthopedics landscape with peers of mid-market scale suggests opportunities for distribution partnerships, contract manufacturing collaboration, and co-marketing with compatible spine and trauma device manufacturers to widen market reach and reduce sales cycle time.